386 related articles for article (PubMed ID: 24289611)
21. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
[TBL] [Abstract][Full Text] [Related]
22. Broad Spectrum Peptide Vaccine Design Against Hepatitis C Virus.
Dewi SK; Ali S; Prasasty VD
Curr Comput Aided Drug Des; 2019; 15(2):120-135. PubMed ID: 30280672
[TBL] [Abstract][Full Text] [Related]
23. Computational prediction of vaccine potential epitopes and 3-dimensional structure of XAGE-1b for non-small cell lung cancer immunotherapy.
Tarek MM; Shafei AE; Ali MA; Mansour MM
Biomed J; 2018 Apr; 41(2):118-128. PubMed ID: 29866600
[TBL] [Abstract][Full Text] [Related]
24. Multi-epitope DnaK peptide vaccine against S.Typhi: An in silico approach.
Verma S; Sugadev R; Kumar A; Chandna S; Ganju L; Bansal A
Vaccine; 2018 Jun; 36(28):4014-4022. PubMed ID: 29861180
[TBL] [Abstract][Full Text] [Related]
25. Structure-based peptide mimicry of tumor-associated antigens.
Ohtaki A; Kieber-Emmons T; Murali R
Monoclon Antib Immunodiagn Immunother; 2013 Feb; 32(1):1-5. PubMed ID: 23600498
[TBL] [Abstract][Full Text] [Related]
26. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
[TBL] [Abstract][Full Text] [Related]
27. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
[TBL] [Abstract][Full Text] [Related]
28. Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.
Rosendahl Huber SK; Camps MG; Jacobi RH; Mouthaan J; van Dijken H; van Beek J; Ossendorp F; de Jonge J
PLoS One; 2015; 10(6):e0127969. PubMed ID: 26046664
[TBL] [Abstract][Full Text] [Related]
29. Designing B-Cell Epitopes for Immunotherapy and Subunit Vaccines.
Singh H; Gupta S; Gautam A; Raghava GP
Methods Mol Biol; 2015; 1348():327-40. PubMed ID: 26424284
[TBL] [Abstract][Full Text] [Related]
30. Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity.
Tian H; He Y; Song X; Jiang L; Luo J; Xu Y; Zhang W; Gao X; Yao W
Cancer Lett; 2018 Aug; 430():79-87. PubMed ID: 29778570
[TBL] [Abstract][Full Text] [Related]
31. Epitope-Based Peptide Vaccine Design against Fructose Bisphosphate Aldolase of
Elamin Elhasan LM; Hassan MB; Elhassan RM; Abdelrhman FA; Salih EA; Ibrahim H A; Mohamed AA; Osman HS; Khalil MSM; Alsafi AA; Idris AB; Hassan MA
J Immunol Res; 2021; 2021():8280925. PubMed ID: 34036109
[TBL] [Abstract][Full Text] [Related]
32. An Immunoinformatics Approach in Design of Synthetic Peptide Vaccine Against Influenza Virus.
Lohia N; Baranwal M
Methods Mol Biol; 2020; 2131():229-243. PubMed ID: 32162257
[TBL] [Abstract][Full Text] [Related]
33. [On predicting the T cell and B cell epitopes of platelet membrane glycoprotein II b/ III a antibody from human and mice].
Li Z; Zhang M; Hu H; Liu S; Lu Z
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Oct; 27(5):1146-51. PubMed ID: 21089688
[TBL] [Abstract][Full Text] [Related]
34. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine.
Negahdaripour M; Nezafat N; Eslami M; Ghoshoon MB; Shoolian E; Najafipour S; Morowvat MH; Dehshahri A; Erfani N; Ghasemi Y
Infect Genet Evol; 2018 Mar; 58():96-109. PubMed ID: 29253673
[TBL] [Abstract][Full Text] [Related]
35. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
36. In Silico Design and Evaluation of PRAME+FliCĪD2D3 as a New Breast Cancer Vaccine Candidate.
Taheri-Anganeh M; Savardashtaki A; Vafadar A; Movahedpour A; Shabaninejad Z; Maleksabet A; Amiri A; Ghasemi Y; Irajie C
Iran J Med Sci; 2021 Jan; 46(1):52-60. PubMed ID: 33487792
[TBL] [Abstract][Full Text] [Related]
37. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
Knutson KL; Block MS; Norton N; Erskine CL; Hobday TJ; Dietz AB; Padley D; Gustafson MP; Puglisi-Knutson D; Mangskau TK; Chumsri S; Dueck AC; Karyampudi L; Wilson G; Degnim AC
Clin Cancer Res; 2020 Mar; 26(5):1045-1053. PubMed ID: 31757875
[TBL] [Abstract][Full Text] [Related]
38. Invariant chain-peptide fusion vaccine using HER-2/neu.
Perez SA; Peoples GE; Papamichail M; Baxevanis CN
Methods Mol Biol; 2014; 1139():321-36. PubMed ID: 24619690
[TBL] [Abstract][Full Text] [Related]
39. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
[TBL] [Abstract][Full Text] [Related]
40. Design of a new multi-epitope vaccine against
Chen Z; Zhu Y; Sha T; Li Z; Li Y; Zhang F; Ding J
Epidemiol Infect; 2021 May; 149():e136. PubMed ID: 34032200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
